montelukast sodium
montelukast sodium is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: montelukast sodium; Generic name: MONTELUKAST SODIUM; Drug class: Leukotriene Receptor Antagonist [EPC].
| Brand name | montelukast sodium |
|---|---|
| Generic name | MONTELUKAST SODIUM |
| Drug class | Leukotriene Receptor Antagonist [EPC] |
| Manufacturer | Preferred Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE Montelukast sodium chewable tablets are a leukotriene receptor antagonist indicated for: • Prophylaxis and chronic treatment of asthma in patients 2 years of age and older ( ). • Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older ( ). • Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( ). 1.1 Asthma Montelukast sodium chewable tablets are indicated for the prophylaxis and chronic tr |
| Dosage | 2 DOSAGE AND ADMINISTRATION Administration (by indications): • Asthma ( ): Once daily in the evening for patients 2 years and older. • Acute prevention of EIB ( ): One tablet at least 2 hours before exercise for patients 6 years of age and older. • Seasonal allergic rhinitis ( ): Once daily for patients 2 years and older. • Perennial allergic rhinitis ( ): Once daily for patients 2 years and older. Dosage (by age) ( 2 ): • 15 years and older: one 10-mg tablet. • 6 to 14 years: one 5-mg chewable |
| Warnings | WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of montelukast sodium. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with montelukast sodium use are currently not well understood [see Warnings and Precautions ( )]. Because of the risk of NP |
| Active ingredient(s) | MONTELUKAST |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09b0bc9e-3035-45b4-b61b-4aca70848360 |